Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 7-8/2020

28.01.2020 | images in science and medicine

Tumorous formation of the forehead

verfasst von: Dr. Ivanka Temelkova, Prof. Dr. Georgi Tchernev

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 7-8/2020

Einloggen, um Zugang zu erhalten

Summary

T‑cell non-Hodgkin’s lymphoma (NHL) represents approximately 10% to 15% of all lymphomas in Western countries. We present the case of a 16-year-old girl with nodular erosive tumor formation on the forehead within the previous 3–4 months and clinical evidence of cervical and submandibular lymphadenopathy in parallel. Tuberculosis verrucosa cutis, lupus vulgaris, cutaneous leishmaniasis, pyoderma faciale, sporotrichosis, infected insect bite, B‑cell lymphoma, and atypical acneiform eruption were considered in the differential diagnosis. The patient has undergone therapy with oral ciprofloxacin (2 × 250 mg/d) for 10 days and oral amoxicillin/clavulanic acid (2 × 1 g/d) for 7–8 days, followed by oral clindamycin (2 × 300 mg/d) and oral rifampicin (2 × 300mg/d) for 4 weeks—all without any improvement. Unfortunately, disease progression was observed. Histologic examination revealed evidence of peripheral T‑cell non-Hodgkin’s lymphoma, and the subsequent immunohistochemical study confirmed the diagnosis, showing positive CD3 and CD4 expression and negative CD8, CD20, CD30, CD43, and ALK1 expression. Based on CT, lymph node involvement was found above and below the diaphragm, such that T‑cell lymphoma stage 4E was concluded. CHOEP chemotherapy treatment was initiated, with a favorable clinical outcome after the first cycle.
Literatur
1.
Zurück zum Zitat Evens A, Gartenhaus R. Treatment of T‑cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol. 2004;5(4):289–303.CrossRef Evens A, Gartenhaus R. Treatment of T‑cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol. 2004;5(4):289–303.CrossRef
2.
Zurück zum Zitat Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3‑weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626–33.CrossRef Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3‑weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626–33.CrossRef
3.
Zurück zum Zitat Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2‑ and 3‑weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL‑B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14(6):881–93.CrossRef Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2‑ and 3‑weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL‑B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14(6):881–93.CrossRef
4.
Zurück zum Zitat Huang Y, Lin T, Wu Q, et al. Survival outcomes of T‑cell non-Hodgkin’s lymphoma: a report of 111 cases. Ai Zheng. 2005;24(4):470–4.PubMed Huang Y, Lin T, Wu Q, et al. Survival outcomes of T‑cell non-Hodgkin’s lymphoma: a report of 111 cases. Ai Zheng. 2005;24(4):470–4.PubMed
5.
Zurück zum Zitat Gao Y, Huang H, Lin X, et al. Treatment outcomes and prognostic analyses of relapsed or refractory T‑cell non-Hodgkin’s lymphoma. Ai Zheng. 2007;26(8):909–13.PubMed Gao Y, Huang H, Lin X, et al. Treatment outcomes and prognostic analyses of relapsed or refractory T‑cell non-Hodgkin’s lymphoma. Ai Zheng. 2007;26(8):909–13.PubMed
Metadaten
Titel
Tumorous formation of the forehead
verfasst von
Dr. Ivanka Temelkova
Prof. Dr. Georgi Tchernev
Publikationsdatum
28.01.2020
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 7-8/2020
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-019-00730-4

Weitere Artikel der Ausgabe 7-8/2020

Wiener Medizinische Wochenschrift 7-8/2020 Zur Ausgabe